加载中
JPXHealthcareBiotechnology
最新数据
JP¥43.00
+JP¥1.00 · +2.38%
BrightPath Biotherapeutics Co., Ltd. specializes in the development of innovative cancer immunotherapies. Among its leading candidates is GRN-1201, currently undergoing Phase II clinical studies for non-small cell lung cancer and Phase I studies for melanoma. The company's diverse development portfolio further encompasses BP1101, a neoantigen vaccine; BP1209, a platform for personalized neoantigen cancer vaccines; and BP1401, an agonist for toll-like receptor 9. Other therapeutic avenues include an induced pluripotent stem cell (iPSC)-derived regenerated NKT cell therapy aimed at head and neck cancer, and BP2301, an autologous HER2 chimeric antigen receptor-T (CAR-T) cell therapy targeting solid tumor sarcomas. Beyond its clinical-stage assets, BrightPath Biotherapeutics is also engaged in early-stage discovery efforts for new antibodies, including BP1200, which targets CD73; BP1210, an immune checkpoint inhibitor; and additional antibody candidates such as BP1202, BP1206, and BP1211. Established in Tokyo, Japan, in 2003, the company operated as GreenPeptide Co., Ltd. until its rebranding to BrightPath Biotherapeutics Co., Ltd. in July 2017.
最新数据
JP¥43.00
+JP¥1.00 · +2.38%
盘中时间采用JST。市场数据可能有所延迟。
BrightPath Biotherapeutics Co., Ltd. specializes in the development of innovative cancer immunotherapies. Among its leading candidates is GRN-1201, currently undergoing Phase II clinical studies for non-small cell lung cancer and Phase I studies for melanoma. The company's diverse development portfolio further encompasses BP1101, a neoantigen vaccine; BP1209, a platform for personalized neoantigen cancer vaccines; and BP1401, an agonist for toll-like receptor 9. Other therapeutic avenues include an induced pluripotent stem cell (iPSC)-derived regenerated NKT cell therapy aimed at head and neck cancer, and BP2301, an autologous HER2 chimeric antigen receptor-T (CAR-T) cell therapy targeting solid tumor sarcomas. Beyond its clinical-stage assets, BrightPath Biotherapeutics is also engaged in early-stage discovery efforts for new antibodies, including BP1200, which targets CD73; BP1210, an immune checkpoint inhibitor; and additional antibody candidates such as BP1202, BP1206, and BP1211. Established in Tokyo, Japan, in 2003, the company operated as GreenPeptide Co., Ltd. until its rebranding to BrightPath Biotherapeutics Co., Ltd. in July 2017.
日内区间
当前JP¥43.00
52周区间
当前JP¥43.00
盘中时间采用JST。市场数据可能有所延迟。
BrightPath Biotherapeutics Co., Ltd. specializes in the development of innovative cancer immunotherapies. Among its leading candidates is GRN-1201, currently undergoing Phase II clinical studies for non-small cell lung cancer and Phase I studies for melanoma. The company's diverse development portfolio further encompasses BP1101, a neoantigen vaccine; BP1209, a platform for personalized neoantigen cancer vaccines; and BP1401, an agonist for toll-like receptor 9. Other therapeutic avenues include an induced pluripotent stem cell (iPSC)-derived regenerated NKT cell therapy aimed at head and neck cancer, and BP2301, an autologous HER2 chimeric antigen receptor-T (CAR-T) cell therapy targeting solid tumor sarcomas. Beyond its clinical-stage assets, BrightPath Biotherapeutics is also engaged in early-stage discovery efforts for new antibodies, including BP1200, which targets CD73; BP1210, an immune checkpoint inhibitor; and additional antibody candidates such as BP1202, BP1206, and BP1211. Established in Tokyo, Japan, in 2003, the company operated as GreenPeptide Co., Ltd. until its rebranding to BrightPath Biotherapeutics Co., Ltd. in July 2017.
日内区间
当前JP¥43.00
52周区间
当前JP¥43.00
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（JPY） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 8.4万 JPY | 113.3万 JPY | 7.2万 JPY | 528万 JPY | 1540.8万 JPY |
| 销货成本 | 2.9万 JPY | 3.2万 JPY | 41.3万 JPY | 1861.4万 JPY | 3844万 JPY |
| 毛利 | 5.5万 JPY | 110.1万 JPY | −34.1万 JPY | −1333.4万 JPY | −2303.2万 JPY |
| 研究与开发 | — | 8.88亿 JPY | 7.76亿 JPY | 11.68亿 JPY | 11.36亿 JPY |
| 销售、一般及管理费用 | 12.95亿 JPY | 2.74亿 JPY | 3.79亿 JPY | 2.85亿 JPY | 3.17亿 JPY |
| 营业费用 | 12.95亿 JPY | 11.62亿 JPY | 11.55亿 JPY | 14.54亿 JPY | 14.53亿 JPY |
| 利息收入 | 1.6万 JPY | 6.9万 JPY | 1.2万 JPY | 2万 JPY | 2.7万 JPY |
| 利息支出 | — | — | — | 6.1万 JPY | 36.2万 JPY |
| 折旧和摊销 | — | — | 39.5万 JPY | 1671.9万 JPY | 3512.3万 JPY |
| 营业利润 | −12.95亿 JPY | −11.61亿 JPY | −11.55亿 JPY | −14.67亿 JPY | −14.76亿 JPY |
| 净利润 | −13.05亿 JPY | −11.51亿 JPY | −11.68亿 JPY | −14.86亿 JPY | −14.84亿 JPY |
公司数据更新于 2026年10月17日。
近期已公布业绩
近期已公布业绩
AI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
